** Shares in Swiss-American eye care group Alcon ALCC.S drop 9.4% on revised 2025 outlook, impacted by U.S. tariffs, and Q1 results below estimates
** "This outlook incorporates a gross tariff impact of approximately $80 million, which is expected to pressure cost of net sales," the company said
** Alcon is more exposed than fields like cardiology, as ophthalmology procedures are often elective and can be delayed, said BTIG analyst Ryan Zimmerman ahead of results, commenting on U.S. impact, adding as well shares might be falling on recession fears
** The stock is on track for its worst day since March 2020, when it closed 10.6% lower
(Reporting by Anastasiia Kozlova)
((Anastasiia.Kozlova@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.